Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
e-FabRIC - SARBECOVIRUS
- Development stage
- Preclinical
- Lead developer
- Fabentech
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Parenteral
01
Overview
e-FabRIC - SARBECOVIRUS (also known as EID treatment #3) is a broad-spectrum passive immunotherapy being developed by Fabentech in collaboration with the e-FabRIC consortium (including the University of Cambridge). The therapeutic candidate consists of equine polyclonal F(ab')2 antibody fragments generated using an innovative hyperimmunization strategy. This strategy utilizes a mosaic-8b nanocage antigen presenting receptor-binding domains (RBDs) from eight different sarbecoviruses. The resulting polyclonal antibodies are designed to neutralize a wide range of viruses within the Sarbecovirus family (including SARS-CoV-2 and its variants) and prevent severe respiratory diseases. The program is currently in the proof-of-concept stage of development.
- Other names
- SARBECOVIRUSe-FabRIC
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on e-FabRIC - SARBECOVIRUS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on e-FabRIC - SARBECOVIRUS.